Business Wire

Philips Launches Brand-New Version of SpeechLive Speech-to-Text Solution

Del

Speech Processing Solutions, the world number one in professional dictation, has launched a brand new version of their Philips SpeechLive dictation and speech recognition workflow solution. The cloud-based solution saves busy professionals’ time and resources by allowing them to be more flexible and turn their voice into written documents quicker than ever before. The latest version of the solution comes with improved usability, new features and enhanced stability for an even more efficient dictation workflow.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171205005110/en/

Philips SpeechLive (Photo: Business Wire)

Philips SpeechLive (Photo: Business Wire)

New SpeechLive Upload Client

The enhanced upload client automatically feeds audio files from dictation recorders straight into the SpeechLive system. The new feature works on Windows computers with all Philips devices including the Philips Pocket Memo, SpeechAir and Voice Tracers. Even customers using non-Philips audio recording devices can take advantage of this time-saving innovation. Users only need to simply plug in their dictation recorder to their PC and the files will transmit automatically.

Email notification for transcriptionists

Another new feature of SpeechLive 8.5 is that transcriptionists receive automatic email notifications whenever new dictations arrive in their SpeechLive intray. This way transcriptionists can attend to important tasks quicker than before. “We wanted to improve the workflow capabilities for our users, to enable them to get their tasks done even quicker than before” explains Dr Thomas Brauner, CEO of Speech Processing Solutions.

Transcription and speech recognition service

Philips SpeechLive offers two additional productivity-boosting services to their users: Philips Speech Recognition Service and Philips Transcription Service. “The transcription service is perfect for when your assistant or transcriptionist is out of the office or simply too busy. Our highly trained transcriptionist staff will take care of even complex transcriptions for you and deliver them back to you quickly” adds Dr Brauner.

Free trial with free included speech recognition minutes

Philips provides a completely free 30-day trial of SpeechLive, where customers can test the solution themselves. The free trial includes 10 free speech recognition as well as 10 free transcription service minutes, so users can test these two additional services as well.

Visit www.speechlive.com to sign up for a free trial now.

About Speech Processing Solutions

Speech Processing Solutions is the global number one in professional dictation solutions. Founded in Austria in 1954 as part of Philips, the company has been the driving force behind innovative speech-to-text solutions for over 60 years. The company has developed ground-breaking products, such as the mobile Philips SpeechAir device, the Philips PocketMemo voice recorder, the Philips SpeechMike Premium USB dictation microphone and the Philips voice recorder app for smartphones, thus delivering its promise of excellence and outstanding quality. Thanks to the latest innovation, Philips SpeechLive, designed as a cloud-based workflow solution, recording dictations is quicker and easier than ever. The tailored range of products and services offered by Speech Processing Solutions helps professional users to save time and resources and to work at maximum efficiency.

Follow Speech Processing Solutions:

Facebook: http://www.facebook.com/philipsvoicetracer

Instagram: https://www.instagram.com/philips_dictation/

Twitter @speech_com: http://www.twitter.com/speech_com

YouTube: http://www.youtube.com/philipsdictation

LinkedIn: http://www.linkedin.com/company/speech-processing-solutions

Contact information

Your contact for further information:
Speech Processing Solutions
Lea Pachta
lea.pachta@speech.com
Tel: +43 160529-1744
www.philips.com/dictation

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i